Skip to main content
Top
Published in: Current Rheumatology Reports 12/2014

01-12-2014 | Inflammatory Muscle Disease (RG Cooper, Section Editor)

Amyopathic Dermatomyositis: Definitions, Diagnosis, and Management

Authors: Elizabeth E. Bailey, David F. Fiorentino

Published in: Current Rheumatology Reports | Issue 12/2014

Login to get access

Abstract

Amyopathic dermatomyositis can be a challenging diagnosis because patients lack traditional muscle findings. “Clinically amyopathic” dermatomyositis (CADM) accounts for the presence of subclinical muscle disease in some of these patients. These patients represent a substantial minority of dermatomyositis cases and have similar co-morbidities to “classic” dermatomyositis patients, including interstitial lung disease and malignancy. Clinically amyopathic dermatomyositis patients should not be considered as a distinct clinical entity from “classic” dermatomyositis, as they share antibody sub-types and associated co-morbidities, likely representing clinical spectrum of a common disease. It is essential for the clinician to be familiar with the clinical presentation of clinically amyopathic dermatomyositis, in order to facilitate early, accurate diagnosis and appropriate clinical management.
Literature
1.
go back to reference Bendewald MJ, Wetter DA, Li X, Davis MD. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol. 2010;146:26–30.PubMedCrossRef Bendewald MJ, Wetter DA, Li X, Davis MD. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol. 2010;146:26–30.PubMedCrossRef
2.
3.
go back to reference Sontheimer RD. Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects. Dermatol Clin. 2002;20:387–408.PubMedCrossRef Sontheimer RD. Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects. Dermatol Clin. 2002;20:387–408.PubMedCrossRef
4.
go back to reference Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol. 2006;54:597–613.PubMedCrossRef Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol. 2006;54:597–613.PubMedCrossRef
5.
go back to reference Ghazi E, Sontheimer RD, Werth VP. The importance of including amyopathic dermatomyositis in the idiopathic inflammatory myositis spectrum. Clin Exp Rheumatol. 2013;31:128–34.PubMedCentralPubMed Ghazi E, Sontheimer RD, Werth VP. The importance of including amyopathic dermatomyositis in the idiopathic inflammatory myositis spectrum. Clin Exp Rheumatol. 2013;31:128–34.PubMedCentralPubMed
6.
go back to reference Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol. 2002;46:626–36.PubMedCrossRef Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol. 2002;46:626–36.PubMedCrossRef
7.
go back to reference Euwer RL, Sontheimer RD. Amyopathic dermatomyositis (dermatomyositis sine myositis): presentation of six new cases and review of the literature. J Am Acad Dermatol. 1991;24:959–66.PubMedCrossRef Euwer RL, Sontheimer RD. Amyopathic dermatomyositis (dermatomyositis sine myositis): presentation of six new cases and review of the literature. J Am Acad Dermatol. 1991;24:959–66.PubMedCrossRef
8.
9.
go back to reference El-Azhary RA, Pakzad SY. Amyopathic dermatomyositis: retrospective review of 37 cases. J Am Acad Dermatol. 2002;46:560–5.PubMedCrossRef El-Azhary RA, Pakzad SY. Amyopathic dermatomyositis: retrospective review of 37 cases. J Am Acad Dermatol. 2002;46:560–5.PubMedCrossRef
10.
go back to reference Cao H, Parikh TN, Zheng J. Amyopathic dermatomyositis or dermatomyositis-like skin disease: retrospective review of 16 cases with amyopathic dermatomyositis. Clin Rheumatol. 2009;28:979–84.PubMedCrossRef Cao H, Parikh TN, Zheng J. Amyopathic dermatomyositis or dermatomyositis-like skin disease: retrospective review of 16 cases with amyopathic dermatomyositis. Clin Rheumatol. 2009;28:979–84.PubMedCrossRef
11.
go back to reference Gitiaux C, Kostallari E, Lafuste P, et al. Whole microvascular unit deletions in dermatomyositis. Ann Rheum Dis. 2013;72:445–52.PubMedCrossRef Gitiaux C, Kostallari E, Lafuste P, et al. Whole microvascular unit deletions in dermatomyositis. Ann Rheum Dis. 2013;72:445–52.PubMedCrossRef
12.
go back to reference Stonecipher MR, Jorizzo JL, Monu J, Walker F, Sutej PG. Dermatomyositis with normal muscle enzyme concentrations: a single-blind study of the diagnostic value of magnetic resonance imaging and ultrasound. Arch Dermatol. 1994;130:1294–9.PubMedCrossRef Stonecipher MR, Jorizzo JL, Monu J, Walker F, Sutej PG. Dermatomyositis with normal muscle enzyme concentrations: a single-blind study of the diagnostic value of magnetic resonance imaging and ultrasound. Arch Dermatol. 1994;130:1294–9.PubMedCrossRef
13.
go back to reference Lam WWM, Chan H, Chan YL, et al. MR imaging in amyopathic dermatomyositis. Acta Radiol. 1999;40:69.PubMedCrossRef Lam WWM, Chan H, Chan YL, et al. MR imaging in amyopathic dermatomyositis. Acta Radiol. 1999;40:69.PubMedCrossRef
14.
go back to reference Park JH, Olsen NJ, King L, et al. Use of magnetic resonance imaging and P-31 magnetic resonance spectroscopy to detect and quantify muscle dysfunction in the amyopathic and myopathic variants of dermatomyositis. Arthritis Rheum. 1995;38:68–77.PubMedCrossRef Park JH, Olsen NJ, King L, et al. Use of magnetic resonance imaging and P-31 magnetic resonance spectroscopy to detect and quantify muscle dysfunction in the amyopathic and myopathic variants of dermatomyositis. Arthritis Rheum. 1995;38:68–77.PubMedCrossRef
15.
go back to reference Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52:1571–6.PubMedCrossRef Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52:1571–6.PubMedCrossRef
16.
go back to reference Nakashima R, Imura Y, Kobayashi S, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology. 2010;49:433–40.PubMedCrossRef Nakashima R, Imura Y, Kobayashi S, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology. 2010;49:433–40.PubMedCrossRef
17.
go back to reference Hoshino K, Muro Y, Sugiura K, et al. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology. 2010;49:1726–33.PubMedCrossRef Hoshino K, Muro Y, Sugiura K, et al. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology. 2010;49:1726–33.PubMedCrossRef
18.
go back to reference Koga T, Fujikawa K, Horai Y, et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology. 2012;51:1278–84.PubMedCrossRef Koga T, Fujikawa K, Horai Y, et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology. 2012;51:1278–84.PubMedCrossRef
19.
go back to reference Hamaguchi Y, Fujimoto M, Matsushita T, et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS ONE. 2013;8:e60442.PubMedCentralPubMedCrossRef Hamaguchi Y, Fujimoto M, Matsushita T, et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS ONE. 2013;8:e60442.PubMedCentralPubMedCrossRef
20.
go back to reference Cottin V, Thivolet-Bejui F, Reynaud-Gaubert M, et al. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis, and polymyositis. Eur Respir J. 2003;22:245–50.PubMedCrossRef Cottin V, Thivolet-Bejui F, Reynaud-Gaubert M, et al. Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis, and polymyositis. Eur Respir J. 2003;22:245–50.PubMedCrossRef
21.
go back to reference Kang EH, Lee EB, Shin KC, Im CH, Chung DH, Han SK, et al. Interstitial lung disease in patients with polymyositis, dermatomyositis, and amyopathic dermatomyositis. Rheumatology. 2005;44:1282–6.PubMedCrossRef Kang EH, Lee EB, Shin KC, Im CH, Chung DH, Han SK, et al. Interstitial lung disease in patients with polymyositis, dermatomyositis, and amyopathic dermatomyositis. Rheumatology. 2005;44:1282–6.PubMedCrossRef
22.
go back to reference Mukae H, Ishimoto H, Sakamoto N, et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest. 2009;136:1341–7.PubMedCrossRef Mukae H, Ishimoto H, Sakamoto N, et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest. 2009;136:1341–7.PubMedCrossRef
23.
go back to reference Yamasaki Y, Yamada H, Ohkubo M, et al. Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan. J Rheumatol. 2011;38:1636–43.PubMedCrossRef Yamasaki Y, Yamada H, Ohkubo M, et al. Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan. J Rheumatol. 2011;38:1636–43.PubMedCrossRef
24.
go back to reference Ye S, Chen X, Lu X, et al. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol. 2007;26:1647–54.PubMedCrossRef Ye S, Chen X, Lu X, et al. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol. 2007;26:1647–54.PubMedCrossRef
25.
go back to reference Chen YJ, Wu CY, Shen JL. Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study. Br J Dermatol. 2001;144:825–31.PubMedCrossRef Chen YJ, Wu CY, Shen JL. Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study. Br J Dermatol. 2001;144:825–31.PubMedCrossRef
26.
go back to reference Azuma K, Hidehiro Y, Ohkubo M, et al. Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis, and clinically amyopathic dermatomyositis. Mod Rheumatol. 2011;21:178–83.PubMedCrossRef Azuma K, Hidehiro Y, Ohkubo M, et al. Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis, and clinically amyopathic dermatomyositis. Mod Rheumatol. 2011;21:178–83.PubMedCrossRef
27.
go back to reference Fung WKJ, Chan HLH, Lam WMW. Amyopathic dermatomyositis in Hong Kong – association with nasopharyngeal carcinoma. Int J Dermatol. 1998;37:659–63.PubMedCrossRef Fung WKJ, Chan HLH, Lam WMW. Amyopathic dermatomyositis in Hong Kong – association with nasopharyngeal carcinoma. Int J Dermatol. 1998;37:659–63.PubMedCrossRef
28.
go back to reference Chen Z, Cao M, Plana MN, et al. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res. 2013;65:1316–24.CrossRef Chen Z, Cao M, Plana MN, et al. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res. 2013;65:1316–24.CrossRef
Metadata
Title
Amyopathic Dermatomyositis: Definitions, Diagnosis, and Management
Authors
Elizabeth E. Bailey
David F. Fiorentino
Publication date
01-12-2014
Publisher
Springer US
Published in
Current Rheumatology Reports / Issue 12/2014
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-014-0465-0

Other articles of this Issue 12/2014

Current Rheumatology Reports 12/2014 Go to the issue

Health Economics and Quality of Life (M Harrison, Section Editor)

Economics of Stratified Medicine in Rheumatoid Arthritis

Pediatric Rheumatology (S Ozen, Section Editor)

Enthesitis-Related Arthritis: Time to Re-define?

Inflammatory Muscle Disease (RG Cooper, Section Editor)

Ongoing Developments in Sporadic Inclusion Body Myositis

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.